Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 24Melanoma 19Glioblastoma 13Neuroblastoma 6Glioma 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Wilms Tumor 2Seminoma 2Rhabdomyosarcoma 2Osteosarcoma 2Neoplasm Metastasis 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hodgkin Disease 2Gliosarcoma 2Central Nervous System Neoplasms 2Astrocytoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Ipilimumab × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡